The global age-related vision dysfunction market garnered a market value of US$ 90 Billion in 2023 and is expected to accumulate a market value of US$ 130 Billion by registering a CAGR of 3.7% in the forecast period 2022 to 2033.
The general public's desire to correct and enhance their eyesight as a consequence of increased eye disorders, an aging population, and a variety of other causes is likely to boost the market for age-related vision dysfunction products throughout the forecast period. The adoption of electronic gadgets has been rapidly increasing. People frequently utilize such gadgets for extended periods of time. As a result, more and more individuals are suffering from age-related vision dysfunction, including Asthenopia, and people have begun to use vision care products, particularly vision care eye drops and vision care capsules.
Moreover, poor nutrition and a lack of attention to health are two other issues that are projected to raise demand for the age-related vision dysfunction market. As a result of poor eating, an increasing number of people are experiencing partial or complete eyesight loss. The adoption of electronic gadgets has increased rapidly. Furthermore, vision care products are now more widely available than ever before. Because of such a robust logistics and supply chain network, vision care items such as eyeglasses, cooling glasses, and so on may be transferred quickly within a region or from one nation to another. This is also expected to boost the age-related vision dysfunction market throughout the projected period.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 90 Billion |
| Anticipated Forecast Value (2033) | US$ 130 Billion |
| Projected Growth Rate (2023 to 2033) | 3.7% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for age-related vision dysfunction is projected to increase at a CAGR of 3.7% during the forecast period between 2022 and 2033, reaching a total of US$ 130 Billion in 2033, according to a report from Future Market Insights (FMI). From 2017 to 2022, sales witnessed significant growth, registering a CAGR of 2%.
The prevalence of rising eye disorders among individuals from all walks of life is predicted to fuel demand for age-related vision dysfunction, notwithstanding a major increase. The number of patients attending eye care hospitals has increased due to a rise in incidences of cataracts and glaucoma. According to WHO figures, more than 4.5 million individuals are blind as a result of glaucoma. This is concerning, and it has pushed glaucoma patients to adopt preventive measures.
An Increase in the Proportion of Geriatrics to Encourage Market Expansion
As people age, their eye lenses get stiffer, making it difficult to focus on objects in close proximity. This disorder is known as presbyopia, and it is frequent in persons over the age of 70.
This is usually corrected by using bifocal or progressive lenses. During the projection period, this is likely to improve growth prospects of age-related vision dysfunction.
Advancements in Ophthalmic Diagnostic and Treatment Technologies to boost Adoption
The technical developments that are occurring in this sector are the primary drivers of the age-related vision dysfunction industry. The use of nanotechnology in vision care is predicted to revolutionize the market.
Nanotechnology is now being used to detect eye pressure, cure retinal disorders, and help patients recover from glaucoma faster. Furthermore, robots are used in conjunction with human intelligence to precisely place surgical equipment during eye surgery. Artificial retinas with electrodes are used to replace injured retinas. This might increase future demand for age-related vision dysfunction treatment.
Increasing Awareness-raising Campaigns concerned with Eye Dysfunction
Whether it is the government or large corporations, they are all taking measures to raise awareness about age-related vision dysfunction and its treatment. The World Health Organization (WHO) and the International Agency for the Prevention of Blindness (IAPB) partnered with the Indian government to create VISION 2020. They also put on World Sight Day and other activities.
The goal was to raise awareness about various eye disorders and the procedures to take to keep healthy eyes. This might boost the age-related vision dysfunction market throughout the predicted period. Artificial retinas with electrodes are used to replace injured retinas. This might increase future demand for age-related vision dysfunction treatments.
Principal Consultant
High Price of Medication to Hamper Market Growth
The high pricing of medications is going to put pressure on corporations and drug makers, particularly on therapies with a high price (i.e. gene therapies) that provide no additional major advantages.
Rapid Technological Development for Widening Profit Margins
During the projected period, the Chinese age-related vision dysfunction market is predicted to develop at a healthy CAGR of 3.6%. Some of the reasons driving the Chinese age-related vision dysfunction market are the raising geriatric population, rapid technological development, and a growing inclination for superior eye care goods.
According to a Lancet investigation, there were more than 45 million individuals in China with moderate visual impairment, 4.6 million with severe vision impairment, and about 8.7 million with blindness. Furthermore, according to studies, China is one of the world's largest markets for age-related vision dysfunction treatments. Because of technical improvements, China's top businesses are offering novel vision care goods at cheap prices.
On the other hand, according to FMI research, the India age-related vision dysfunction market is estimated to develop at a CAGR of 3% over the forecast period. People have begun to adopt sedentary lifestyles as cities have grown in size. As a result, individuals begin to acquire numerous health concerns, the most evident of which is eye damage in many cases.
Furthermore, the use of technological gadgets is increasing. This opens up a big possibility for the vision care sector in the future. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 3.5% in the assessment period 2023-2033.
Growing Senior Population to Accelerate Market Growth
According to FMI research, the North American age-related vision dysfunction market is predicted to develop at a CAGR of 3.6% during the forecast period. The market is likely to be driven by a growing senior population, favorable government policies, and an increase in the incidence of eye illnesses among individuals of all ages.
According to the Centers for Disease Control and Prevention, almost 12 million Americans over the age of 40 have vision impairment. This has been connected to an increase in diabetes incidence in the region. The government and several corporate entities are launching awareness campaigns to keep the issue under control.
Furthermore, the leading businesses are utilizing cutting-edge technology to provide the greatest products possible. Aside from that, the rapid expansion of the E-Commerce industry is predicted to fuel the market in the United States. The United States is predicted to be the top country in North America, with a market share of 33.8% in the area.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Glaucoma Segment Trends to enhance Sales Prospects
The increasing incidence of glaucoma, rising attempts to raise awareness about glaucoma, and technical breakthroughs in the area of ophthalmology are the primary drivers driving the growth of the glaucoma treatment sector.
Glaucoma is the world's second-largest cause of blindness. This is usually caused by increased intraocular tension. The basic purpose of treatment is to reduce intraocular tension. This is accomplished by either decreasing aqueous fluid secretion or boosting its outflow. Although glaucoma medications alleviate symptoms, there is no cure for this ailment.
Key start-up players in the age-related vision dysfunction are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key age-related vision dysfunction start-ups are as follows:
The main market participants are taking all feasible measures to execute the proper activities in order to lessen the rising number of age-related vision dysfunction sufferers globally. They are getting into strategic relationships with start-ups to solve some of the issues that patients confront when undergoing treatment for this purpose. The leading stakeholders are on a quest to create minimally invasive surgical treatments for this purpose. Key players in the age-related vision dysfunction market are:
Recent Developments:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 90 Billion |
| Market Value in 2033 | US$ 130 Billion |
| Growth Rate | CAGR of 3.7% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global age-related vision dysfunction market to expand at a 3.7% value CAGR by 2033
The global Age Related Vision Dysfunction market is estimated at a market value of US$ 90 Billion
The global Age Related Vision Dysfunction market is expected to garner a market value of US$ 130 Billion
As per Future Market Insights, Asia Pacific is expected to grow at a CAGR of 3.5% in the assessment period 2023 to 2033.
Aerie Pharmaceuticals, Santen Pharmaceutical, Sun Pharma Advanced Research Company Limited, Bausch + Lomb, D Western Therapeutics Institute, Novartis, AbbVie, Eyenovia, Orasis Pharmaceuticals and IVERIC Bio are some prominent Age Related Vision Dysfunction manufacturers
As per Future Market Insights, North America is expected to grow at a CAGR of 3.6% in the assessment period 2023 to 2033.
As per Future Market Insights, Europe is expected to grow at a CAGR of 3.3% in the assessment period 2023 to 2033.
The glaucoma segment is expected to hold the largest market share for Age Related Vision Dysfunction in the forecast period 2023-2033
1. Executive Summary | Age-Related Vision Dysfunction Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dysfunction Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Dysfunction Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dysfunction Type, 2023 to 2033
5.3.1. Cataract
5.3.2. AMD
5.3.3. Glaucoma
5.3.4. Presbyopia
5.4. Y-o-Y Growth Trend Analysis By Dysfunction Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Dysfunction Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Drug, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug, 2023 to 2033
6.3.1. Rocklatan
6.3.2. Eybelis Ophthalmic Solution
6.3.3. Xelpros
6.3.4. Rhopressa
6.3.5. Vyzulta
6.3.6. Glanatec
6.3.7. Simbrinza
6.3.8. Tapcom/DE-111
6.3.9. Azarga/Azorga
6.3.10. Combigan
6.3.11. Lucentis
6.3.12. Eylea
6.3.13. Beovu
6.4. Y-o-Y Growth Trend Analysis By Drug, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Drug, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East & Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. The US
8.2.1.2. Canada
8.2.2. By Dysfunction Type
8.2.3. By Drug
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Dysfunction Type
8.3.3. By Drug
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Dysfunction Type
9.2.3. By Drug
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Dysfunction Type
9.3.3. By Drug
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. The UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Dysfunction Type
10.2.3. By Drug
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Dysfunction Type
10.3.3. By Drug
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Dysfunction Type
11.2.3. By Drug
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Dysfunction Type
11.3.3. By Drug
11.4. Key Takeaways
12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Dysfunction Type
12.2.3. By Drug
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Dysfunction Type
12.3.3. By Drug
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. The US
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Dysfunction Type
13.1.2.2. By Drug
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Dysfunction Type
13.2.2.2. By Drug
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Dysfunction Type
13.3.2.2. By Drug
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Dysfunction Type
13.4.2.2. By Drug
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Dysfunction Type
13.5.2.2. By Drug
13.6. The UK
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Dysfunction Type
13.6.2.2. By Drug
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Dysfunction Type
13.7.2.2. By Drug
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Dysfunction Type
13.8.2.2. By Drug
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Dysfunction Type
13.9.2.2. By Drug
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Dysfunction Type
13.10.2.2. By Drug
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Dysfunction Type
13.11.2.2. By Drug
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Dysfunction Type
13.12.2.2. By Drug
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Dysfunction Type
13.13.2.2. By Drug
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Dysfunction Type
13.14.2.2. By Drug
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Dysfunction Type
13.15.2.2. By Drug
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Dysfunction Type
13.16.2.2. By Drug
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Dysfunction Type
13.17.2.2. By Drug
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Dysfunction Type
13.18.2.2. By Drug
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Dysfunction Type
13.19.2.2. By Drug
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Dysfunction Type
13.20.2.2. By Drug
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Dysfunction Type
14.3.3. By Drug
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Aerie Pharmaceuticals
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Santen Pharmaceutical
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Sun Pharma Advanced Research Company Limited
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Bausch + Lomb
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. D Western Therapeutics Institute
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Novartis
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. AbbVie
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Eyenovia
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Orasis Pharmaceuticals
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. IVERIC Bio
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Age Related Vision Dysfunction Market
